

---

## Press Release

---

### **Interims results of “DIOR – the Spanish registry” presented at AHA (Florida) 2009**

*Hospital del Mar, Barcelona Spain and Eurocor, Bonn Germany* – DIOR is the first approved drug eluting balloon world wide, produced by the leading manufacturer of drug eluting balloons, Eurocor.

During the AHA congress (Florida 2009) Vaquerizo et. al. presented the interims analysis on 191 patients of a real world registry from nine hospitals using the drug eluting balloon DIOR. The overall excellent outcome of this all comer registry is superimposed when analysis of the small vessel subgroup is taken into account. A TLR Rate of 4.8 % at 6 months FU and 0% Thrombosis also at 6 months are excellent for an emerging technology like the drug eluting balloons.

Of particular interest is the outcome of the small vessel subgroup: This subgroup highlights the efficacy of the DIOR drug eluting balloon without using a stent in small vessels (< 2.5 mm diameter). The 6 months follow up (including a 40% angiographic FU) resulted in a TLR of 2, 1% and 0% Thrombosis.

“This result is even better than what we expected from the rational in the usage of Drug eluting balloons. With the small vessel disease being a clinical meaningful indication in PTCA we are happy to offer a superior treatment to our patients with this new technique”, Antonio Serra (chair of the cathlab Hospital del Mare; Barcelona Spain) commented.

“It is very tantalizing to follow the performance of the DEB DIOR in the various indications, small vessels have clearly qualified as a key indication”, Rembert Pogge von Strandmann (head of the clinical department; Eurocor) said.